WO2004045619A1 - Injection de poudre nanometrique de lecithine congelee et sechee d'un acide ursolique et son procede de preparation - Google Patents
Injection de poudre nanometrique de lecithine congelee et sechee d'un acide ursolique et son procede de preparation Download PDFInfo
- Publication number
- WO2004045619A1 WO2004045619A1 PCT/CN2003/000969 CN0300969W WO2004045619A1 WO 2004045619 A1 WO2004045619 A1 WO 2004045619A1 CN 0300969 W CN0300969 W CN 0300969W WO 2004045619 A1 WO2004045619 A1 WO 2004045619A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lyophilized
- ursolic acid
- acid
- freeze
- bear
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention belongs to a drug ursolic acid, and relates to a nano-scale lyophilized powder injection of ursolic acid and a preparation method thereof.
- the purpose of the present invention is to provide ten kinds of ursin jelly and its preparation method, so as to improve the whole life.
- the main ingredients of the ten ingredients of the present invention are: bear lyophilization.
- the ten main ingredients are: live 3 ⁇ 4 ⁇ , ursolic acid, ursin nanoparticle composite carrier, and lyophilized auxiliary material.
- the ursolic complex carrier is selected from soy phospholipids and acids.
- excipients in lyophilized excipients Glycine, bt for injection, glucose for injection, dextran, chloro !, sodium glycine, sodium dihydrogen phosphate, and seric acid, ⁇ ⁇ ⁇ ⁇ .
- the preparation method is as follows: after dissolving the bear medical talented agent, adding the carrier soybean lecithin and acid, and heating it to 45 ⁇
- Capacitors can be selected from one or two of acetone.
- Cannabis has the advantages of high stability and bribery. Its average particle size is 209.5 mm, and the drug load is 25.2%. The drug has a table that inhibits and kills J f cancer cells, 1) 53, bcl-2 and Topo-II.
- the weight ratio of live, raw Xiongjiang, and bear fruit in the heterogeneous composite carrier Douban lipid, lyophilized excipient 'ut is: 0.1 to 10: 0.3 to 30: 0 to 10: 0.1 to 20.
- Encapsulated 88.3% of ursolic acid-one bean prepared by J 3 ⁇ 4 has a drug loading of 25.2%.
- the average diameter measured by the laser particle size analyzer was 209.5mm, the Zeta potential was-31.67mV, and the polydispersity was 0.149.
- test drugs 1 Preparation of bear fruit liquid: Take 6660 mg of ursolic acid (99.7%) and dissolve it in 10 ml of 20% propylene glycol water; in the liquid. 2 Ursolic acid-bean brick fat sodium M ⁇ tS is made by itself, and the sample is taken to be equivalent to 835 Omg of ursolic acid dissolved in 1 Oral water, which is increased by 0.7 between each dose group.
- Table 1 LD 5 bears acid injection.
- RPMI-1640 medium is a GIBC0 product, made by three-distillation according to the instructions, and added with 10% (V / V) fetal bovine serum, 100U / raL penicillin and 100U / mL streptomycin, sterilized by 0.22U filter, 4 .
- Fetal calf serum is a product of Qinghu Calf Applied Research Station, Jinhua City, Zhejiang province;
- MTT [3- (4, 5)-bismethyl-ethylene-p-zozole (2, 5)-dimethyl odorization Tetrazolium is a product of SIGMA Company in the United States.
- End-labeling kit [Terrai-na ldeoxy lnuc 1 eo t idy 1 Transferase (TdT)] is a product of American Promega Company; DIG-dUTP is a product of German BM company; Anti-DIG-Biotin is a product of American SIGMA company; Beijing Pharmaceutical Industry Research Laboratory products; exempt kits are the products of the company, primary antibodies are imported packaging, SABC and DAB kit are products of Wuhan Baode Co., Ltd.
- SMMC- 7721 function ear 3 ⁇ 4 to 3 ⁇ 4 ⁇ long-term SMMC- 7721 cells are often transformed, adjust the cells to 1 X lOVmL, seeded at 96 ⁇ I ⁇ , 100 ⁇ l per well, cultured with RM-1640 Age-diluted bears ⁇ ⁇ Wuzhi Na 10 medicines-erythroside (VP 16 ) to the required solid level, 24 hours after cell seeding, drip into a 96-well plate, 100 ⁇ per well.
- VP 16 Wuzhi Na 10 medicines-erythroside
- the experimental group is ursolic soy lecithin Nano-powder injection + S MC-7721, P-day '1 ⁇ ⁇ Photo group is VP 16 + S MC-7721, Yin' ⁇ In the photo group is CM + SMMC- 7721, each group is provided with 3 compound holes, adjusted Fully train cells at 200 L in a 37 ° C, 5 ° / »C0 2 incubator, and continue to culture for 1 day, 3 days, 5 days, and Likou 3 ⁇ 43 ⁇ 4 5 mgAiL of M ⁇ T, 20 L / well.
- Inhibition rate (E) (1-0D / 0D ⁇ 100%.
- Bel- 2 tablets are non-fine ⁇ f Hai coloring for one-step nuclear village staining: hematoxylin lrain, washed with ⁇ J, hydrochloric acid alcohol 2min "5min, washed with water, 15s-20s, washed with water, all 3 skin slides after gradient alcohol ⁇ Dimethyl ⁇ if Ming 15min, coverslip. Results: ⁇ m, p53, and TopoII were positive cells with yellow to brownish yellow, and bcl-2 was stained with cytoplasm to light yellow as positive cells. Use low selection The 3 backgrounds are the clearest, and the DAB is significantly higher than the most satisfactory area. Change the number ⁇ Do not calculate the number of positive cells per 500 cells. Take the average number of positive cells in 3 areas as the positive rate. Weak positive (+): ⁇ 20% ; Strong positive (+ + +):>70%; Moderate positive (+ +): ⁇ Between the two.
- ursin can inhibit the expression of p53, bcl-2 and Topo II, thereby inhibiting and killing the growth of cancer cells.
- the drug substance was found in the process of three cell lines: at the low agricultural level of 0.1, 0.5, 2 ⁇ / ⁇ 1
- the inhibitory effect is weak, and its inhibition with the prolonged effect
- the rates are increasing compared to fMan, and the inhibition is strong at 3 ⁇ 4110, 50 g / ml, and the prolongation of Itt's action time ⁇
- the rate of growth increases quickly, until the 3rd day! ] More than 95%, found in the process of the three cell lines:
- the inhibitory effect of # 3 ⁇ 40.1, 0.5, 2 ⁇ 1 is also weak, and the increase of the action time ⁇
- the growth rate of the control rate is relatively higher than that of ft.
- the inhibitory effect is stronger at 10 ⁇ / ⁇ , and the inhibitory rate is increasing with the extension of the effect time, but the inhibitory effect on ⁇ 549 is weaker than the other two cells. At 50 ⁇ , the inhibitory effect is delayed with the effect time. The growth trend reached more than 95% by the third day. As shown above, for three cell lines ⁇ -29, ⁇ 549 and Hep-G 2 , the drug exerts its maximum effect for 4 days. It is shown that the preparation of the present invention has slow-release silk.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/535,955 US8287889B2 (en) | 2002-11-21 | 2003-11-17 | Freeze-dried lecithin nanometer powder injection of ursolic acid and its preparation method |
JP2004552351A JP4896401B2 (ja) | 2002-11-21 | 2003-11-17 | ウルソル酸−大豆レシチン凍結乾燥ナノ粒子注射剤およびその製造方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021477116A CN1243538C (zh) | 2002-11-21 | 2002-11-21 | 熊果酸豆磷脂纳米粒冻干粉针及制备方法 |
CN02147711.6 | 2002-11-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004045619A1 true WO2004045619A1 (fr) | 2004-06-03 |
Family
ID=4751251
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2003/000969 WO2004045619A1 (fr) | 2002-11-21 | 2003-11-17 | Injection de poudre nanometrique de lecithine congelee et sechee d'un acide ursolique et son procede de preparation |
Country Status (4)
Country | Link |
---|---|
US (1) | US8287889B2 (zh) |
JP (1) | JP4896401B2 (zh) |
CN (1) | CN1243538C (zh) |
WO (1) | WO2004045619A1 (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102499925B (zh) * | 2011-10-21 | 2015-11-11 | 上海中医药大学 | 一种中性粒细胞弹性蛋白酶抑制剂 |
JP6026785B2 (ja) * | 2011-10-31 | 2016-11-16 | 富士フイルム株式会社 | 水性組成物 |
CN102631352A (zh) * | 2012-04-23 | 2012-08-15 | 武汉利元亨药物技术有限公司 | 熊果酸的医学新用途 |
EP2842545B1 (en) * | 2012-04-24 | 2020-02-12 | Osaka University | Method for producing an aqueous dispersion of drug nanoparticles and use thereof |
CN106983769A (zh) * | 2016-01-21 | 2017-07-28 | 易以木 | 用于抗辐射的熊果酸山药多糖组合物及其制备方法 |
CN106983810A (zh) * | 2016-01-21 | 2017-07-28 | 易以木 | 山药多糖、枇杷叶提取物抗辐射口服制剂及制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1157716A (zh) * | 1995-11-16 | 1997-08-27 | 日本化学研究股份有限公司 | 转移抑制剂 |
CN1266680A (zh) * | 1999-12-27 | 2000-09-20 | 陈武 | 乌索酸在制备治疗病毒性肝炎药物中的应用 |
CN1333679A (zh) * | 1998-11-20 | 2002-01-30 | Rtp药品公司 | 可分散的磷脂稳定的微粒 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03287531A (ja) * | 1990-03-31 | 1991-12-18 | Snow Brand Milk Prod Co Ltd | 膵炎治療薬 |
JPH03287530A (ja) * | 1990-03-31 | 1991-12-18 | Snow Brand Milk Prod Co Ltd | 免疫抑制剤 |
CZ299790B6 (cs) * | 1996-08-22 | 2008-11-26 | Skyepharma Canada Inc. | Kompozice mikrocástic ve vode nerozpustné látky, farmaceutická kompozice, zpusob prípravy stabilních cástic, mikrocástice ve vode nerozpustné nebo slabe rozpustné slouceniny, kompozice obsahující tyto mikrocástice a zpusob prípravy mikrocástic |
CA2326456C (en) * | 1998-03-30 | 2008-12-23 | Rtp Pharma Inc. | Composition and method of preparing microparticles of water-insoluble substances |
US6267989B1 (en) * | 1999-03-08 | 2001-07-31 | Klan Pharma International Ltd. | Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions |
US6261607B1 (en) * | 1999-10-19 | 2001-07-17 | Thomas Newmark | Composition for promoting prostate health containing selenium and herbal extracts |
CN1450900A (zh) * | 2000-07-31 | 2003-10-22 | 日清奥利友株式会社 | 抗肿瘤剂 |
WO2002052956A1 (fr) * | 2000-12-27 | 2002-07-11 | The Nisshin Oillio, Ltd. | Boisson ou aliment antitumoral |
CN1231209C (zh) * | 2002-11-21 | 2005-12-14 | 武汉利元亨药物技术有限公司 | 熊果酸聚乳酸纳米粒冻干粉针剂及制备方法 |
-
2002
- 2002-11-21 CN CNB021477116A patent/CN1243538C/zh not_active Expired - Lifetime
-
2003
- 2003-11-17 US US10/535,955 patent/US8287889B2/en active Active
- 2003-11-17 JP JP2004552351A patent/JP4896401B2/ja not_active Expired - Lifetime
- 2003-11-17 WO PCT/CN2003/000969 patent/WO2004045619A1/zh active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1157716A (zh) * | 1995-11-16 | 1997-08-27 | 日本化学研究股份有限公司 | 转移抑制剂 |
CN1333679A (zh) * | 1998-11-20 | 2002-01-30 | Rtp药品公司 | 可分散的磷脂稳定的微粒 |
CN1266680A (zh) * | 1999-12-27 | 2000-09-20 | 陈武 | 乌索酸在制备治疗病毒性肝炎药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN1243538C (zh) | 2006-03-01 |
CN1410064A (zh) | 2003-04-16 |
JP2006508968A (ja) | 2006-03-16 |
US8287889B2 (en) | 2012-10-16 |
US20060034933A1 (en) | 2006-02-16 |
JP4896401B2 (ja) | 2012-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110101684A (zh) | 一种生物正交靶向的细胞膜仿生纳米颗粒及其制备方法和用途 | |
CN106699896B (zh) | 一种可自组装成水凝胶的肿瘤杀伤性多肽及其应用 | |
CN109999197A (zh) | 肿瘤靶向的纳米复合物、制备方法及其在声动力介导的肿瘤精准治疗中的应用 | |
CN115252560A (zh) | 一种基于天然产物的自组装纳米粒及其制备方法和应用 | |
CN110870868A (zh) | 包含亚甲蓝类染料、营养素或/和抗肿瘤化合物的药物组合物及其应用 | |
CN108926535B (zh) | SapC-磷脂纳米囊泡冻干制剂、 其制备方法及用途 | |
JP5466173B2 (ja) | 水溶性、カチオン性および両親媒性の薬学的に活性な物質を投与するためのドラッグ・デリバリー・システム | |
WO2004045619A1 (fr) | Injection de poudre nanometrique de lecithine congelee et sechee d'un acide ursolique et son procede de preparation | |
CN112516073A (zh) | 一种治疗肿瘤的多组分凝胶缓释药物组合物 | |
Su et al. | Treatment of chemotherapy-induced neutropenia in a rat model by using multiple daily doses of oral administration of G-CSF-containing nanoparticles | |
WO2021114605A1 (zh) | 一种基于糖基金属框架材料的肝靶向治疗药物及制备方法 | |
CN105418731B (zh) | 鹿茸蛋白提取物及其药学用途 | |
Yin et al. | Artificial cells delivering itaconic acid induce anti-inflammatory memory-like macrophages to reverse acute liver failure and prevent reinjury | |
CN109223827A (zh) | 水溶性的富勒烯结构在制备治疗肺纤维化的药物中的应用 | |
WO2021219113A1 (zh) | 异戊酰螺旋霉素类化合物或其组合物在制备治疗免疫失调的药物中的应用 | |
CN104814959B (zh) | 磁性斑蝥酸钠维生素b6复方制剂及其制备方法 | |
KR101002672B1 (ko) | 크로몰린 함유 페길화된 리포좀 및 그 제조방법 | |
Cai et al. | Enhanced Transdermal Peptide‐Modified Flexible Liposomes for Efficient Percutaneous Delivery of Chrysomycin A to Treat Subcutaneous Melanoma and Intradermal MRSA Infection | |
CN115531554B (zh) | 合成致死纳米药物组合载体及其在制备治疗gbm靶向药物上的应用 | |
CN112220778B (zh) | 一种用于肺动脉高压治疗的联合递送系统及其制备方法 | |
CN113975248B (zh) | 肝癌靶向诊疗一体化的纳米颗粒及其应用 | |
CN111202818B (zh) | 一种中药组合物及其制备方法和应用 | |
CN113546046B (zh) | 一种乳铁蛋白修饰的广藿香醇脂质体及其制备方法和应用 | |
CN108354896B (zh) | 一种雷替曲塞水凝胶及其制备方法和用途 | |
CN114437193A (zh) | 一种金-蜂毒肽纳米杂化物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2006034933 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004552351 Country of ref document: JP Ref document number: 10535955 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase | ||
WWP | Wipo information: published in national office |
Ref document number: 10535955 Country of ref document: US |